The Minister of Labor, Health and Solidarity of France, Catherine Vautrin, has announced that GSK’s vaccine against respiratory syncytial virus (RSV) will be reimbursed starting next fall. Arexvy, which is now available for marketing in the European Union, is indicated for the prevention of lower respiratory tract disease (LRTI) caused by RSV in adults 60 years of age and older.
“The French High Health Authority (HAS) will issue its opinion this summer on the GSK vaccine against RSV in older people and, logically, from the autumn we will be able to have it available,” explained the French minister. “This is extremely important news, we are going to save lives”has also stressed that “with vaccination perhaps the use of antibiotics can be reduced.”
The High Authority of Health will issue its opinion “this summer” on the GSK vaccine against the bronchiolitis virus in seniors and “logically, from the fall, we will be able to have it”, says the Minister of Labor and Health Catherine Vautrin on @bleumayenne @CaVautrin pic.twitter.com/aNoiKkCbuP
— France Bleu Mayenne (@bleumayenne) February 22, 2024
The approval of Arexvy was based on the latest data from the AReSVi-006 phase III trial on its efficacy published last year 2023. The study showed that the efficacy of the GSK vaccine was 82.6 percent against the disease, while that percentage increased against serious illness: a 94.1 percent of effectiveness.
Likewise, it was observed a tolerable safety profile and the effectiveness of Arexvy was confirmed in patients with comorbiditiessuch as underlying cardiorespiratory and endocrine-metabolic pathologies, associated with a greater risk of suffering serious consequences in the event of illness.
Competition in the United Kingdom
For its part, the UK Secretary of State for Health, Therese Coffeyhas tendered a contest for the supply of immunization products indicated for the prevention of RSV throughout life (four lots):
- A monoclonal antibody for babies: the provision of a product indicated for the prevention or protection against RSV in infants from birth, including premature infants, weighing less than five kilograms by direct passive immunization of the infant using a monoclonal antibody.
- A vaccine that provides maternal protection: the supply of a product indicated for the prevention or protection of RSV in infants through a vaccine administered to pregnant women.
- A vaccine for older adults (annual cohort): the provision of a product indicated for the prevention or protection against RSV in a routine, single annual cohort of older adults.
- A vaccine for older adults (annual cohort and recovery volume):the provision of a product indicated for the prevention or protection against RSV in a single annual routine cohort of older adults with a catch-up for multiple cohorts during the first year.
2024-02-27 17:09:20
#France #finance #GSKs #RSV #vaccine #autumn
